Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘NIBR’

A novel bispecific ADC to watch out for

Companies think they see gold in the distance, while ignoring the narrowing, darker hazards close by

If 2024 was the year of topoisomerase-I antibody-drug conjugates (ADCs) then 2025 is likely to herald a different series of trends within this niche.

Adding on extra payloads or targets may seem like a logical extension – as witnessed by the flurry of bispecific and dual-payload ADCs. This approach often ignores the many underlying complexities and challenges involved because these are highly complex and sophisticated agents to develop.  It’s not simply a matter of swapping out different elements akin to Lego bricks and hoping for the best.

In this article, we discuss a number of issues facing companies chasing the ADC dream, as well as an early example of an intriguing novel ADC target to pay attention to going forwards.

In the long run, the near and far might turn out to be relative, depending on your perspective…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Wielding AI’s power for scientific good

Protein structure Source: Generate Biomedicine

With the incredibly rapid advances in artificial intelligence and machine learning (AI/ML) models of late there is growing potential for an exponential impact on R&D, especially in the field of oncology.

While some observers may well be sceptical or wary, there are ways we can use these tools for greater scientific good by generating better, smarter drug designs rather than just mere productivity gains.

As more companies are exploring difficult or intractable targets, the need for enhanced computational power is increasing.

In our latest post, we combine some amazing discovery findings from the upcoming American Society of Hematology (ASH) meeting with a story around the evolution of computational models and how they can help some brave companies and researchers develop new medicines with a difference rather than yet another me-too drug.

Are you ready for a tempestuous revolution rather than a slow paced evolution?

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Pointing the way forward

Continuing our series on Kaizen in cell therapy, we now switch both angles and companies to explore a different round early stage developments.

It was clear at ASH that to some, these were perceived as a head scratcher, while for others they were considered the best thing since sliced bread in the niche, so opinions on the controversy clearly differ quite broadly!

What’s the skinny then – and why does it all matter?

Curious to learn more?

To continue reading our latest highlights on oncology new product development including expert commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

AACR22 Preview 1 – Key topics to watch out for

Opening the door on our AACR22 coverage

Yes, it’s that time of the year already…

In our first Preview from the AACR annual meeting coming up next month, we’re going to highlight a couple of key topics of interest to many of our readers and also offer some context for where the selected fields are currently at and just as importantly, where they are likely headed.

The abstracts haven’t dropped yet – the regular abstract titles, authors, and text will be released tomorrow (March 8th) at 4:30 pm ET – although based on our knowledge of the field, recently published data, or presentations already rolling out we can put a good picture together of what’s what and where things are at…

BSB subscribers can read our latest commentary – you can either log-in or click to access.

This content is restricted to subscribers

Through the keyhole look at an emerging area of drug development

Every now and then one comes across a scientific paper detailing a novel approach, which leads to a resurgence of interest and endeavours from the field at large.

A time when you sit, eagerly read the prose carefully and think, ‘Wow, just wow!’

This is one of those such quiet groundbreaking moments… and the future impact may well be more far reaching in oncology than many first realise.

BSB subscribers can read our latest commentary – you can either log-in or click to access.

This content is restricted to subscribers

The Evolving Competitive Landscape for TIM-3

The start of a New Year is a good time to take stock of where we’ve come from and where we’re going in the fast-paced world of oncology new product development.

Upregulation doesn’t always mean a protein is a valid target, but in some cases it just might…

In this latest post, we’re revisiting T cell immunoglobulin and mucin domain-containing protein 3 – or TIM-3 in short – and taking a closer look at the evolving competitive landscape in this niche.

One company targeting it is Novartis, who have an anti-TIM–3 antibody MBG453 in development. In this post we have an expert interview with a scientist who is a pioneer in the emerging field of TIM-3 biology.

There’s also a review of some of the recent important scientific papers on TIM-3 biology, as well as commentary on data presented at ASH19 that we expect may feature in presentations at JPM20 next week, not to mention be the focus of future interim updates should the data turn out to show some promise in certain settings.

If you have an interest in targeting novel immune checkpoints and want to find out more about where the field is at with TIM-3, then this post is for you.

Curious to find out more about our latest oncology coverage and get a heads up on additional insights from our latest thought leader interview, analysis, and commentary? Subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Things we need to think about ahead of ASCO17

We are finally at the end of our AACR 2017 post meeting analysis and coverage with the final interview from Washington DC on deck. Timely wise, it’s actually quite a relevant one given the news last week on mixed results with clinical trials involving checkpoint blockade.

Dr Jeff Engelman AACR17

Just as we learned that immunotherapy agents can stop working over time, as well as the majority of patients don’t respond at all to begin with, there are concerted research efforts ongoing by both academia and industry to explore mechanisms of immune escape, resistance and modulating the tumour microenvironment.

Here we explore the intersection of targeted therapy-IO combinations, resistance and immune escape, transcription factors and other interesting new areas of development.

Also included is commentary from a leading KOL, which is NOT available on the recent Novel Targets podcast episode on overcoming immunotherapy resistance – readers should check that out first before reading this article, as this is more advanced.

Subscribers can login to read our latest industry expert interview

This content is restricted to subscribers

error: Content is protected !!